Previous 10 | Next 10 |
BASEL, Switzerland, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant’s President and CEO, will present at the Everco...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Shares of Myovant Sciences (NYSE: MYOV) are rising today, up by 12% as of 3:03 p.m. EST, after receiving some favorable coverage from the analyst community. The clinical-stage biotech skyrocketed earlier in the week in the wake of strong results in a phase 3 drug tria...
Aravive (NASDAQ: ARAV ) +212% on promise of lead candidate . More news on: Aravive, Inc., Cancer Genetics, Inc., My Size, Inc., Stocks on the move, Read more ...
November 20, 2019 Palm Beach, FL – November 20, 2019 – It appears that the reign of the opioid drugs in the global pain management markets could be coming to an end. While opioids have long been the ‘best’ choice to address the pain patients suffer from var...
The stock market once again found itself lacking clear direction, with different indexes moving in opposite directions. Most of the same big-picture issues remained on investors' minds, and weakness in the retail sector weighed on the generally upbeat sentiment that market participants have had ...
When it comes to pharmaceutical or biotech stocks, positive news with regards to any product that is in development almost always leads to a rise in the stock price. That is exactly what happened with MYOV stock this morning after Myovant Sciences Ltd (NYSE:MYOV) provided updates with reg...
Gainers: SAExploration (NASDAQ: SAEX ) +85% . More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., Karuna Therapeutics, Inc., Stocks on the move, Read more ...
Shares of Myovant Sciences (NYSE: MYOV) are skyrocketing today, up 161% as of 10:45 a.m. EST, after the clinical-stage biotech released results from its phase 3 HERO study. The HERO study was designed to test the safety and efficacy of Myovant's lead compound, relugolix, as...
SAExploration Holdings (NASDAQ: SAEX ) +183% on $130M of new projects in Alaska, Canada and the Middle East. More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., The Medicines Company, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...